Finance & Capital Markets

  1. Biotech M&A Trends With Allan Shaw 3/21/2022

    On this episode of the Business of Biotech, Allan Shaw waxes on his expectations for mergers, acquisitions, and collaborative partnership opportunities for new and emerging biotechs in 2022 and beyond. We tackle questions biotech leaders should be asking about intentionality, what's attractive to potential suitors, and why startups that aren't prepared to take a candidate to the finish line have already conceded a major factor in partnership or buyout negotiations. Don't miss Shaw's advice for startup success in a suddenly tumultuous market.

  2. The Legend Steve Gorlin's Golden Rules 11/1/2023

    Shortly after Thalidomide became a household word—albeit a very, very bad one—a biotech investor bought it for a couple hundred grand. Who on earth would want a drug pulled from the market for causing birth defects? Steve Gorlin did.

  3. CAR T Therapy Cost Control With Laurence Cooper, M.D., Ph.D. 10/26/2020

    Controlling the cost of personalized medicine: We go behind the scenes of the effort to build a system that simplifies production and reduces the cost of non-viral T cell therapies with Ziopharm Oncology CEO Laurence Cooper, M.D., Ph.D.

  4. Venture Philanthropy For Type 1 Diabetes With T1D Fund's Katie Ellias 1/19/2022

    The JDRF's T1D Fund is exemplary of an indication-specific advocacy group's aggressive pursuit of a cure through venture philanthropy. Put simply, unlike traditional VC firms who entertain myriad and often diverse pitches from biotech startups, the T1D fund creates financial and advisory incentives for the biotechs in its portfolio to pursue candidates and formalize programs around Type 1 Diabetes therapies.

  5. Biotech M&A Anomalies With Allan Shaw 8/22/2022

    While many clinical-stage biopharmas are contracting or holding the line through the current market slump, Portage Biotech leaders Ian Walters, Allan Shaw, and company are making moves. The company recently acquired Tarus Therapeutics and iOx Therapeutics Ltd., extending its pipeline and positioning itself to meet some aggressive investor expectations. On this episode of the Business of Biotech, Shaw dissects the deals, digging into the M&A strategy at Portage and offering advice from the batter's box to leaders of early-stage biotechs.

  6. From Bayer To Startup Bio With AltruBio's Dr. Judy Chou 9/20/2021

    Judy Chou, Ph.D. was a big-pharma MVP. She earned her academic stripes in the hallowed halls of Yale, the Max Planck Institute, and Harvard Medical School before taking on principal scientist roles at AbbVie, Pfizer, and Genentech. That experience parlayed into SVP positions at Tanvex, Medvation, back to Pfizer, and on to Bayer, where she was most recently SVP and Global Head of Biotech before taking the leap into the startup scene as President & CEO at AltruBio in 2020. On today's episode of the Business of Biotech, Dr. Chou shares personal and professional insight into how she's applied what she learned in Big Bio to transform a clinical-stage developer of mAbs designed to treat a broad range of immunological diseases.

  7. A CFO's Prescription For Biopharma Success 3/22/2021

    Friend of the show and life sciences CFO extraordinaire Allan Shaw joins us for a discussion on the steps to biopharma success from an insider's perspective. We discuss the incremental steps that are necessary and common to success in the biologic therapy space, and the mistakes Shaw has seen in his many engagements with new and emerging biotech firms. From capital resource allocation to personnel decision making to preparing for the bubble to burst, listen in as Shaw shares his unfiltered advice.

  8. Origins Of A Biopharma VC Deal With Bernat Olle, Ph.D. And Parag Shah 6/21/2023

    Here's a behind-the-scenes breakdown of how Vedanta Biosciences secured the support of K2 Health Ventures in its recent $100 million+ financing to fund a pivotal Phase 3 study.

  9. Episode 5: Finding Funding In Volatile Times With Ben Zeskind 8/13/2020

    Ben Zeskind launched his biotech, Immuneering, in the throes of the Great Recession. The company earned a $20 million series A round to fund the development of its pipeline at the outset of the COVID-19 pandemic. Along the way, it bootstrapped its way from bioinformatics company to fledgling biopharma. On this episode of The Business Of Biotech, Zeskind shares his experience-based wisdom on finding funding in volatile times.

  10. Pivoting To RNA With Circio's Dr. Erik Digman Wiklund 9/1/2024

    This week, it’s another “Business of Biotech-meets-Business-of-RNA” takeover with Circio CEO Erik Digman Wiklund, Ph.D. and guest co-host Anna Rose Welch of Advancing RNA. While Circio’s legacy is in cancer immunology (it still boasts a cancer vaccine candidate targeting KRAS driver mutations), the company made a bold pivot, of sorts, when it committed headlong to the circular RNA future. Now, it’s in the throes of fine-tuning a platform for the development of novel circRNA medicines for rare disease, vaccines, and cancer.